Longfellow Investment Management Co. LLC acquired a new position in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 200,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,590,000. Longfellow Investment Management Co. LLC owned 0.42% of Sucampo Pharmaceuticals at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. bought a new position in Sucampo Pharmaceuticals during the 2nd quarter worth about $117,000. Trexquant Investment LP bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter valued at about $122,000. SG Americas Securities LLC grew its holdings in shares of Sucampo Pharmaceuticals by 5.6% in the 2nd quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock valued at $126,000 after acquiring an additional 631 shares in the last quarter. Nine Chapters Capital Management LLC bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter valued at about $127,000. Finally, Stifel Financial Corp bought a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at about $131,000. 64.55% of the stock is currently owned by institutional investors and hedge funds.
Sucampo Pharmaceuticals, Inc. (SCMP) traded down $0.05 during trading on Friday, reaching $17.95. The company had a trading volume of 4,366,200 shares, compared to its average volume of 3,567,125. Sucampo Pharmaceuticals, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $18.75. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. The company has a market capitalization of $849.02, a PE ratio of -5.46, a P/E/G ratio of 5.06 and a beta of 1.45.
SCMP has been the subject of several analyst reports. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Tuesday, October 17th. UBS Group decreased their price objective on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, October 12th. Maxim Group set a $23.00 price objective on Sucampo Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, December 7th. B. Riley raised their price objective on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, December 6th. Finally, BidaskClub upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 5th. Six investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $21.58.
In related news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now owns 52,023 shares in the company, valued at $858,379.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.13% of the company’s stock.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.